Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand Neffy’s reach beyond the U.S.

Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals. But after the recent approval of neffy, the San Diego drugmaker is poised for an October launch and a “blue sky opportunity,” according to analysts at Leerink Partners.

The U.S. Food and Drug Administration has approved ARS Pharmaceuticals' (SPRY.O) nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions.

The Food and Drug Administration on Tuesday declined to approve a nasal spray that would have been the first needle-free alternative to injectors like EpiPen for treating severe allergic reactions, a decision that “surprised” developer ARS Pharmaceuticals and could push back the anticipated treatment’s arrival until late next year.

A committee of the Food and Drug Administration's outside advisers voted Thursday in favor of an epinephrine nasal spray product, clearing a key hurdle for what could soon be the first needle-free option for treating severe allergic reactions.